Our Team
Mission
In pursuit of delivering patients the fastest possible visual restoration gene therapy
More than a million patients worldwide with inherited retinal disease are still waiting for an effective treatment that can end their fear of going blind.
Seeing them firsthand, a mission-driven ophthalmologist founded Restore Vision to develop a gene therapy to stop—even reverse—the disease in its tracks.
We can see a future where this too will be a treatable condition. And we want you to see it too.
Leadership
-
Yusaku Katada, M.D., Ph.D.
President & CEO -
Hikaru Miyazaki
Executive Vice President & COO -
Naoyuki Nakada, Ph.D.
SVP, Preclinical Lead
Advisers
-
Katsuyuki Nagai, Ph.D.
CMC advisor -
Shinichi Koizumi, Ph.D.
Executive Advisor -
Tsutomu Uchiyama, Ph.D.
IP Strategy Advisor -
Ken Shimokawa, Ph.D.
Strategic Advisor
Investors
About Us
Company Name | Restore Vision Inc. |
---|---|
Location |
|
Established | November 14, 2016 |
Representative | Yusaku Katada, M.D., Ph.D. |
Business Activities | Research and development of regenerative medicine |